

UNIVERSITY *of* WASHINGTON

# Advances in Stroke Recovery: A Physical Medicine and Rehabilitation Perspective

---

Nicole Mazwi, MD

Associate Professor

Director of Stroke Rehabilitation

Department of Rehabilitation Medicine





MICHAEL E. DEBAKEY  
HIGH SCHOOL FOR HEALTH PROFESSIONS

# Outline

---

> When:

- Acute care physiatry

> What:

- Biomarkers

> How:

- Treatments

- > Medications

- > Activity

- > Brain stimulation

W

# A Paradigm Shift

---

## Old Paradigm:

- I. Medical stability
- II. Surgical stability
- III. Rehabilitation

## New Paradigm:

- I. Medical stability
- II. Surgical stability
- Early Rehabilitation

# Physiatry in Acute Care

---



Acute  
Management



Prognostication/  
Goal-setting



Disposition

W

# Acute Management

## We have many arrows...

- Early mobility options and techniques
- Spasticity and contracture management
- Bracing prescription and application
- Use of electrical nerve and muscle stimulation in immobilized patients
- Delirium management
- Agitation management
- Sympathetic hyperactivity management
- Neurogenic bowel/bladder management
- Sleep-wake cycle regulation
- Appropriate use and timing of stimulant therapy
- Evaluation and management of patients with DoC
- Patient/family education
- Identifying barriers to rehabilitation candidacy
- Continuity of care for patients transitioning to the floor
- etc....




W

# ICU-acquired Impairments in Stroke

- ***ICU-acquired weakness:*** 25-60%
  - Muscle strength loss: Up to 5% per week of bedrest
  - Detectable weakness in up to 1/3 patients on MV for 7 days
- ***Delirium:*** 50-80% surgical, trauma, burn ICU
- ***Psychiatric symptoms:*** 28% (depression), 24% (anxiety), 22% (PTSD)
- Problems persist beyond acute care hospitalization
  - Loss of muscle bulk, proximal muscle weakness, fatigue evident at 1 yr follow-up

# Post-Intensive Care Syndrome (PICS)

*New or worsening impairments in physical, cognitive, or mental health status arising after critical illness and persisting beyond acute care hospitalization.*



# Sleep-wake Cycle Disruption

- Up to 70% of neuro patients
- Poorer functional recovery, depression, cardiac and cerebrovascular morbidity
- In a recent study in hyperacute stroke, physiologic sleep cycles were universally absent
- Suspicion for OSA must be high
- Management Effort for Delirium and Insomnia in Patients with Acute Ischemic Stroke (MEDIAS) study:
  - #1: Sleep hygiene - Minimizing disruptions and turning lights on or off in the hospital room to mimic actual time of day are steps that can be easily implemented.
  - Pharmacotherapy: zolpidem improving sleep but also providing neuroprotection and improved functional recovery.
  - Melatonin well-tolerated, low potential for dependence - reinforce normal circadian rhythm

# Agitation

- Up to 86% of neuro patients in the ICU
- DDx: central, constipation, pain, urinary retention, delirium, anxiety, seizure, new ICH, PTA, hypoxia, PSH

## Management:

- Conservative: redirection, 1:1, net beds, restraints, delirium precautions, mobilization
- Dexmedetomidine – may lower risk of delirium compared to benzos and opioids
- Beta-blockers – reduction in Overt Agitation Scale
- AEDs – VPA (less sedation, cog impairment), CBZ (irritability, disinhibition)
- Antipsychotics/Neuroleptics – atypicals, Haldol?
- Benzodiazepines – midazolam, lorazepam (cog impairment, slow recovery)


# Hypoarousal

Barrier to participation in early rehab efforts and transitioning to the next level of care.

Modafinil, amantadine and methylphenidate prescribing patterns have recently been studied in the ICU setting with low rates of adverse events and improved GCS score in TBI and stroke patients.

Modafinil in Recovery after Stroke (MIRAS) study: early use of modafinil to treat fatigue and lethargy in patients with moderate to severe stroke was associated with improved discharge disposition without significant adverse events.

# Delirium



# Spasticity

- 5-40% of patients after UMN injury (higher in patient with initial UE impairment)
- Hemorrhagic stroke > ischemic subtypes
- Severe paresis > minor paresis
- Rarely in acute stroke but important to identify early
- Impaired mobility, difficulty with ADLs, pain, increased caregiver burden.
- Treatment:
  - Non-pharmacologic: NMES, ROM (moderate quality evidence), splints, serial casting
  - Pharmacologic: Tizanidine, Dantrolene, Valium, Baclofen, Botox
    - Possibility of early motor recovery and fluctuations tone



# Early Mobilization

Application of physical activity within the first 2 to 5 days of critical illness or injury

(Cameron et al., 2015)



- ROM/Active-assisted exercises
- Bed mobility activities
- Cycle ergometer
- ADLs
- Transfer training
- Postural stability, static and dynamic balance
- Ambulation with or without mobility aids

(Morris et al., 2008; Needham et al, 2010; Goodson et al., 2017)

# Biomarkers: Outcomes

## Some basic principles:

PM&R has a *long* lens

Acute care teams tend to the nihilistic


Recognize multilaterality of goal-setting

- Huddle in advance

- Family expectations must be clear

- "Environmental" considerations are 2ndary

Data to guide prognostication is limited...humility is crucial



W

# What is a Good Outcome?

---

- modified Rankin Scale [mRS] ≤2
- Fugl-Meyer Motor >75
- ARAT 39-57
- 6 Minute Walk Test >400m
- Timed Up and Go <10s
- Barthel Index >91
- Functional Independence Measure (FIM) 100

W

# Biomarker: Clinical Scores

- FUNC
- ICH score
- THRIE-c

## Calculate FUNC Score

**ICH volume (cc)**

**Age (yrs)**

**ICH Location**

**GCS**

**Pre-ICH Cognitive Impairment**

**Calculate FUNC Score**

W

# Biomat

Actual Change in UE-FM



# Recovery

Proportional recovery

Limited recovery

# Biomarkers: Imaging/Neurophysiologic

Proportional recovery after stroke depends on corticomotor integrity

Annals of  
NEUROLOGY

Winston D. Byblow PhD , Cathy M. Stinear PhD, P. Alan Barber MBChB, PhD, Matthew A. Petoe PhD, Suzanne J. Ackerley BPhy, PhD



Are early measured resting-state EEG parameters predictive for upper limb motor impairment six months poststroke?

Mique Saes <sup>a</sup>, Carel G.M. Meskers <sup>a, b</sup>, Andreas Daffertshofer <sup>c</sup>, Erwin E.H. van Wegen <sup>a</sup>, Gert Kwakkel <sup>a, b, d</sup>  , on behalf of the 4D-EEG consortium

**Resting-State Functional Connectivity Magnetic Resonance Imaging and Outcome After Acute Stroke**

Josep Puig , Gerard Blasco, Angel Alberich-Bayarri, Gottfried Schlaug, Gustavo Deco, Carles Biarnes, Marian Navas-Martí, Mireia Rivero, Jordi Gich, Jaume Figueras, Cristina Torres, Pepus Daunis-i-Estadella, Celia L Oramas-Requejo, Joaquín Serena, Cathy M Stinear, Amy Kuceyeski, Carles Soriano-Mas, Götz Thomalla, Marco Essig, Chase R. Figley, Bijoy Menon, Andrew Demchuk,

**Stroke**


**BRAIN**  
A JOURNAL OF NEUROLOGY

**Functional potential in chronic stroke patients depends on corticospinal tract integrity **

Cathy M. Stinear , P. Alan Barber, Peter R. Smale, James P. Coxon, Melanie K. Fleming, Winston D. Byblow


**W**

# Biomarker: Acute CST Integrity




Explains  $\approx 20\%$  of the variance in magnitude of UE recovery, even after controlling for the severity of initial impairment.

# Biomarker: EEG




W

# Biomarker: Resting-State Functional Connectivity



# Biomarker: MEPs using TMS



+MEP has PPV of 86-93%, as predictor of good 90-day UE motor outcome

Kimberley T, et al. Arch PM&R 2022

De Gruyter online 2017

Vora et al. 2022


Wang et al. 2020

W

# Neural Repair

---

- > Experience-dependent Brain Plasticity → Improved behavioral outcomes
- > Goal:
  - 1. Increase function in surviving tissue
  - 2. Promote clinically favorable brain plasticity




W

# Neural Repair

## Targets in Biological Post-stroke Pathways

### Mechanisms

- Gene expression
- Growth inhibitors
- Capillary outgrowth
- Axonal sprouting
- Synaptogenesis
- Glial activation



### Brain changes

- activity
- network
- structure



### Result

### Behavioral recovery

W

# Neural Repair: Medication

---

FLAME



Chollet et al. Lancet Neurol 2011  
FOCUS Collab. Lancet 2019

FOCUS



# Neural Repair: Medication

---

Sinemet vs. Placebo prior to therapy

Two trials: 53 and 593 patients

- + Arm and leg motor function
- + Ability to walk independently



W

# Neural Repair: Activity

---

Constraint-Induced Movement Therapy (CIMT)

EXCITE, VECTORS



# Neural Repair: Activity

## LEAPS Trial: BWSTT

- Early vs. Late vs. Home
- Outcome: Improved gait speed

*Positive for ALL groups – 52% of patients with improved gait speed*



# Neural Repair: Robotics

---

- > Traditional stroke rehabilitation: repetitive exercise → facilitate motor learning and build strength
  - Acute: PROM → AAROM
- > Robotic devices:
  - simple, repetitive tasks with consistency
  - guide patient through specific motions; maintaining a prescribed level of support and restrict undesired movements
  - “stand-in” for the skilled clinician AND collect objective quantitative data
  - software: compelling games and physical challenges → increased patient engagement



# End-organ Robotics

**ReoGo**



**Amadeo**



**MIT-Manus Shoulder-Elbow**



# Exoskeleton Workstations

Armeo



Lokomat



W

# Wearable Technology

## Myomo



## Ekso GT



Evidence limited, growing:

- + Fugl-Meyer
- + Strength
- ? ADLs
- + Functional Ambulation Scale
- + 10m and 6m Walk Test
- + Trunk Control Test

Molteni et al. 2017

Meeker et. al. Intl Conf on Rehab 2017

Peters et al. Arch PMR 2016

Mehrholz et al. Cochrane 2017

# Robotics: Data

---

## > **InMotion**

- Decrease motor impairment, improve function, enduring change
- Robot provided similar, but not superior benefit for motor performance

## > **Armeo**

- Acute Rx: 30 sessions x 60min + SOC. Nonsuperior but "enjoyable and efficient"
- Treatment group (chronic): higher Fugl-Meyer scores compared to dose-matched conventional therapy, but not clinically meaningful

## > **Lokomat**

- Mixed in acute and chronic phase; nonsuperior vs slightly better functional and motor outcomes

Klamroth-Marganska et al. 2014

Krakauer et al. Neurorehabil Neural Repair 2021

Lo et al. NEJM 2010

Volpe et al. 1999



# Robotics: Limitations


---

- > “Experimental” → Cost-prohibitive
- > Low bar for FDA approval
- > Size
- > Human oversight during use




# Neural Repair: Brain Stimulation

- > Transcranial Magnetic Stimulation (TMS)
- > Transcranial Direct Current Stimulation
- > Epidural Stimulation of Cortex




W

# Transcranial Direct Current Stimulation



# Transcranial Direct Current Stimulation

Active electrode over target regions, reference electrode over control region



Anodal electrode → excitability increased.  
Current flow is reversed (cathodal) → excitability decreased

# In Conclusion

---



W

UNIVERSITY *of* WASHINGTON

Thank you

---

W